hologic , inc .notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) determination of the measurement date for the market price of acquirer securities issued in a purchase business combination .the components and allocation of the purchase price , consists of the following approximate amounts: .
[['net tangible assets acquired as of july 13 2006', '$ 800'], ['in-process research and development', '10200'], ['developed technology and know how', '39500'], ['customer relationship', '15700'], ['trade name', '3300'], ['order backlog', '800'], ['deferred income taxes', '4400'], ['goodwill', '145900'], ['estimated purchase price', '$ 220600']]
the company has begun to assess and formulate a plan to restructure certain of r2 2019s historical activities .as of the acquisition date the company recorded a liability of approximately $ 798 in accordance with eitf issue no .95-3 , recognition of liabilities in connection with a purchase business combination , related to the termination of certain employees and loss related to the abandonment of certain lease space under this plan of which approximately $ 46 has been paid as of september 30 , 2006 .the company believes this plan will be finalized within one year from the acquisition date and will record any additional liabilities at such time resulting in an increase to goodwill .the final purchase price allocations will be completed within one year of the acquisition and any adjustments are not expected to have a material impact on the company 2019s financial position or results of operation .as part of the purchase price allocation , all intangible assets that were a part of the acquisition were identified and valued .it was determined that only customer relationships , trademarks and developed technology had separately identifiable values .customer relationships represent r2 2019s strong active customer base , dominant market position and strong partnership with several large companies .trademarks represent the r2 product names that the company intends to continue to use .developed technology represents currently marketable purchased products that the company continues to resell as well as utilize to enhance and incorporate into the company 2019s existing products .the estimated $ 10200 of purchase price allocated to in-process research and development projects primarily related to r2s digital cad products .the projects are expected to add direct digital algorithm capabilities as well as a new platform technology to analyze images and breast density measurement .the project is approximately 20% ( 20 % ) complete and the company expects to spend approximately $ 3100 over the year to complete .the deferred income tax asset relates to the tax effect of acquired net operating loss carry forwards that the company believes are realizable partially offset by acquired identifiable intangible assets , and fair value adjustments to acquired inventory as such amounts are not deductible for tax purposes .acquisition of suros surgical systems , inc .on july 27 , 2006 , the company completed the acquisition of suros surgical systems , inc. , pursuant to an agreement and plan of merger dated april 17 , 2006 .the results of operations for suros have been included in the company 2019s consolidated financial statements from the date of acquisition as part of its mammography business segment .suros surgical , located in indianapolis , indiana , develops , manufactures and sells minimally invasive interventional breast biopsy technology and products for biopsy , tissue removal and biopsy site marking. .

Question: what percentage of the estimated purchase price is developed technology and know how?
Answer: 18%